GIUGNO 2026
GYNECOLOGICAL-CANCERS
Prof.ssa Domenica Lorusso
Humanitas San Pio X, Milano, Italia
A Phase 1/2 study of REGN5668, a MUC16×CD28 costimulatory bispecific antibody, in combination with other targeted therapies, in patients with recurrent ovarian or endometrial cancer: Trial in progress update
A phase 1/2 study of ubamatamab (REGN4018), a MUC16×CD3 bispecific antibody, administered alone or in combination with cemiplimab in a low-grade serous ovarian cancer cohort: Trial in progress. Overall survival subgroup analyses for prior taxane use in the phase 3 ROSELLA trial of relacorilant plus nab-paclitaxel versus nab-paclitaxel monotherapy in patients with platinum-resistant ovarian cancer (GOG-3073, ENGOT-ov72, APGOT-Ov10, LACOG-0223, and ANZGOG-2221/2023).
A phase 1/2 study of ubamatamab (REGN4018), a MUC16×CD3 bispecific antibody, administered alone or in combination with cemiplimab in a low-grade serous ovarian cancer cohort: Trial in progress. Overall survival subgroup analyses for prior taxane use in the phase 3 ROSELLA trial of relacorilant plus nab-paclitaxel versus nab-paclitaxel monotherapy in patients with platinum-resistant ovarian cancer (GOG-3073, ENGOT-ov72, APGOT-Ov10, LACOG-0223, and ANZGOG-2221/2023).
LUNG-CANCERS
Prof. Diego Luigi Cortinovis
Fondazione IRCCS San Gerardo dei Tintori, Monza (MB), UniMib, Italia
Prof. Marcello Tiseo
Azienda Ospedaliera-Universitaria Parma, Parma, Italia
Sacituzumab tirumotecan (sac-TMT) plus pembrolizumab (P) versus pembrolizumab (P) as first-line treatment for PD-L1–positive advanced non-small cell lung cancer (NSCLC): Results from the randomized phase 3 OptiTROP-Lung05 study.
Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy in previously untreated advanced squamous non–small cell lung cancer: Overall survival results of the phase 3 HARMONi-6 trial.
First-line treatment patterns of advanced non–small cell lung cancer in patients with and without pre-existing autoimmune diseases
SKIN-CANCERS
Prof. Paolo A. Ascierto
IRCCS Istituto Nazionale Tumori Fondazione G. Pascale, Napoli, Italia
Prof. Paolo Bossi
IRCCS Humanitas Research Hospital, Rozzano (MI), Italia
Dott.ssa Margaret Ottaviano
IRCCS Istituto Nazionale Tumori Fondazione G. Pascale, Napoli, Italia
A multicenter, randomized phase Ib trial to evaluate neoadjuvant immunotherapy combination of nivolumab alone or plus ipilimumab with the IL-2 superkine MDNA11 alone or with tocilizumab in patients with high-risk, surgically resectable melanoma: The NEO-CYT trial.
Skin cancers: quali i principali studi emersi?
AGOSTO 2024
HCM
Prof. Iacopo Olivotto
Università degli Studi di Firenze, Azienda Ospedaliero Universitaria Meyer IRCCS,
Firenze, Italia
Modern medical treatment is better than myomectomy for obstructive hypertrophic cardiomyopathy: pro
Prof. Iacopo Olivotto
Università degli Studi di Firenze, Azienda Ospedaliero Universitaria Meyer IRCCS,
Firenze, Italia
The clinical challenge of managing a patient with HCM
Prof. Maurizio Pieroni
Università degli Studi di Firenze, Azienda Ospedaliera Universitaria Careggi,
Firenze, Italia
Long-term safety and efficacy of mavacamten in obstructive hypertrophic cardiomyopathy: up to 3.5-year follow-up results of the EXPLORER cohort of MAVA-Long-Term Extension study
Prof. Maurizio Pieroni
Università degli Studi di Firenze, Azienda Ospedaliera Universitaria Careggi,
Firenze, Italia
Update Linee Guida
Prof. Milind Desai
Cleveland Clinic, Cleveland,
OH, USA
Real-world experience with mavacamten in obstructive hypertrophic cardiomyopathy: observations from a tertiary care center
Prof. Milind Desai
Cleveland Clinic, Cleveland,
OH, USA
Serial changes in left and right ventricular global longitudinal strain in symptomatic obstructive hypertrophic cardiomyopathy treated with mavacamten: insights from VALOR-HCM trial
Prof. Milind Desai
Cleveland Clinic, Cleveland,
OH, USA
Serial changes in left atrial strain in symptomatic obstructive hypertrophic cardiomyopathy treated with mavacamten: insights from VALOR-HCM trial
Prof.ssa Carolyn Ho
Brigham and Women's Hospital, Harvard Medical School, Boston,
MA, USA
State-of-the-art lecture on novel therapies for hypertrophic cardiomyopathy: recent developments and prospects
Dott. Juan Ramon Gimeno Blanes
Virgen de la Arrixaca University Clinical Hospital,
Murcia, Spagna
Modern medical treatment is better than myomectomy for obstructive hypertrophic cardiomyopathy: con
Dott.ssa Alessandra Milazzo
Azienda Ospedaliera-Universitaria Careggi,
Firenze, Italia
Exploring the effects of mavacamten through hemodynamic force analysis in patients with obstructive hypertrophic cardiomyopathy
Dott.ssa Giorgia Panichella
Azienda Ospedaliera-Universitaria Careggi,
Firenze, Italia
Non-invasive assessment of left ventricular hemodynamic forces in hypertrophic cardiomyopathy
Prof. Farbod Sedaghat-Hamedani
University Hospital Heidelberg,
Heidelberg, Germany
Overview sessione e-posters “Hypertrophic obstructive cardiomyopathy (HOCM): clearing the roadblock”
Prof. Farbod Sedaghat-Hamedani
University Hospital Heidelberg,
Heidelberg, Germany
Assessing the alignment of obstructive hypertrophic cardiomyopathy pharmacological treatments with ESC guidelines in Germany
Dott.ssa Mollie Lowe
Adelphi Real World, Macclesfield,
United Kingdom of Great Britain & Northern Ireland, UK
Clinical characteristics and burden of non-obstructive hypertrophic cardiomyopathy: a real-world survey in Italy and Spain